Press release
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
Includes long-term follow-up data (>5 years) in patients with muscle-invasive bladder cancer and additional studies in colorectal, gastroesophageal and
About this update from Natera, Inc.
[{"type":"text","content":"\nIncludes long-term follow-up data (>5 years) in patients with muscle-invasive bladder cancer and additional studies in colorectal, gastroesophageal and hepatocellular carcinoma\n\n\n AUSTIN, Texas--(BUSINESS WIRE)--\nNatera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its Signatera molecular residual disease (MRD) test being presented at the annual meeting of the American Association for Cancer Research (AACR) taking place April 14 – 19, 2023.\n\n\nNatera and its collaborators will present findings from five studies on Signatera in esophago-gastric adenocarcinoma, muscle-invasive bladder cancer (MIBC), colorectal cancer (CRC) and hepatocellular carcinoma (HCC). Highlights include:\n\n\n\nctDNA prediction of tumor response and recurrence in patients with esophago-gastric carcinoma receiving FLOT + immunotherapy (avelumab) pre- and post-surgery\n\n\n\n\nctDNA prediction of tumor response and recurrence in patients with MIBC, with and without neoadjuvant therapy, with long term follow-up (median 68 months) after radical cystectomy\n\n\n\n\nGenomic profiling of >13,000 patients with early (≤50 years old) vs late (≥60 years old) onset CRC\n\n\n\n\nPotential of ctDNA to guide imaging-based surveillance strategies in patients after surgery for peritoneal metastases from CRC\n\n\n\n\nctDNA as a pharmacodynamic and predictive biomarker in patients with resectable HCC treated with immunotherapy (cemiplimab) pre- and post-surgery\n\n\n\n“We are pleased to share additional Signatera data at this year’s AACR annual meeting that continues to highlight the important role of personalized MRD testing in assessing treatment response and predicting relapse across a broad range of indications,” said Minetta Liu, M.D., chief medical officer of oncology at Natera. “These data presentations underscore Natera’s commitment to generating novel insights on MRD testing and genomic testing to help advance cancer care.”\n\n\nThe full list of Signatera poster presentations at AACR is below.\n\n\nAbstract #2178 | April 17, 9:00 AM - 12:30 PM\nPresenter: Thomas U. Marron, M.D., Ph.D. - Icahn School of Medicine at Mount Sinai\nCirculating tumor DNA (ctDNA) correlates closely with tumor necrosis and relapse-free survival (RFS) in hepatocellular carcinoma (HCC) patients treated with perioperative cemiplimab\n\n\nAbs...